Chapman PB et al. [36] reported the response initially to vemurafenib treatment by approximately 80% of patients with mutant BRAF melanomas, but acquired drug resistance develops in the majority of patients commonly within 1 year. The gene discussed is BRAF; the disease is melanoma.